Loading...
menu
Search
AI Chat
AI Strategies
Products
Markets
News
Resources
Pricing
Home
ETF
CPRX
CPRX
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
CPRX News
Halozyme and Catalyst Report Double-Digit Revenue Growth, Strong Outlook
Jan 24 2026
NASDAQ.COM
Biotech Recovery: Halozyme and Catalyst Stocks Surge Amid Strong Growth
Jan 24 2026
Fool
Texas Instruments Maintains Hold Rating, Price Target Raised to $195
Jan 14 2026
Benzinga
Texas Instruments Stock Performance Strong, Hold Recommended
Jan 14 2026
CNBC
Catalyst Pharmaceuticals Ranked 11th in Forbes' 2026 America's Most Successful Small-Cap Companies
Jan 08 2026
Globenewswire
Catalyst Pharmaceuticals Hosts Inaugural Advocacy Scholars Summit with Notre Dame
Jan 05 2026
Globenewswire
Catalyst Pharmaceuticals CCO Sells 74% of Holdings for ~$256,200
Dec 31 2025
Fool
Catalyst Pharmaceuticals CCO Sells 74% of Shares for $256,200
Dec 31 2025
NASDAQ.COM
Catalyst Pharmaceuticals to Present at 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026
Dec 15 2025
Globenewswire
Catalyst Pharmaceuticals to Present at 44th Annual J.P. Morgan Healthcare Conference
Dec 15 2025
Newsfilter
Daily Upgrade Report for Validea's Joel Greenblatt Strategy - December 12, 2025
Dec 12 2025
NASDAQ.COM
Catalyst Pharmaceuticals Named Among North America's Rapidly Expanding Companies in the 2025 Deloitte Technology Fast 500™
Nov 19 2025
Newsfilter
Catalyst Pharmaceuticals to Join Citi's 2025 Global Healthcare Conference
Nov 18 2025
Newsfilter
Catalyst increases 2025 revenue forecast to $565M–$585M and announces $200M share repurchase initiative.
Nov 06 2025
SeekingAlpha
Catalyst Pharmaceuticals, Inc. Reports Higher Q3 Profit, Surpassing Expectations
Nov 06 2025
NASDAQ.COM
Catalyst Pharmaceuticals to Attend Jefferies Global Healthcare Conference
Nov 03 2025
Newsfilter
Show More News
